<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04861922</url>
  </required_header>
  <id_info>
    <org_study_id>XY3-UFH2021</org_study_id>
    <nct_id>NCT04861922</nct_id>
  </id_info>
  <brief_title>Unfractioned Heparin for Treatment of Sepsis Caused by Abdominal Infection</brief_title>
  <official_title>Low Dose Unfractioned Heparin for Treatment of Sepsis Caused by Abdominal Infection：a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Third Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Third Xiangya Hospital of Central South University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sepsis is the leading cause of death in intensive care units and a major public health&#xD;
      concern in the world. Heparin, a widely used anticoagulant medicine to prevent or treat&#xD;
      thrombotic disorders, has been demonstrated to prevent organ damage and lethality in&#xD;
      experimental sepsis models. However, the efficacy of heparin in the treatment of clinical&#xD;
      sepsis is not consistent. Caspase-11, a cytosolic receptor of LPS, triggers lethal immune&#xD;
      responses in sepsis. Recently, we have revealed that heparin prevents cytosolic delivery of&#xD;
      LPS and caspase-11 activation in sepsis through inhibiting the heparanase-mediated glycocalyx&#xD;
      degradation and the HMGB1- LPS interaction, which is independent of its anticoagulant&#xD;
      properties. In our study, it is found that heparin treatment could prevent lethal responses&#xD;
      in endotoxemia or Gram-negative sepsis, while caspase-11 deficiency or heparin treatment&#xD;
      failed to confer protection against sepsis caused by Staphylococcus aureus, a type of&#xD;
      Gram-positive bacterium. It is probably that other pathogens such as Gram-positive bacteria&#xD;
      might cause death through mechanisms distinct from that of Gram-negative bacteria.&#xD;
      Peptidoglycan, a cell-wall component of Gram-positive bacteria, can cause DIC and impair&#xD;
      survival in primates by activating both extrinsic and intrinsic coagulation pathways, which&#xD;
      might not be targeted by heparin. We speculate that the discrepancy between the previous&#xD;
      clinical trials of heparin might be due to the difference in infected pathogens. Thus,&#xD;
      stratification of patients based on the type of invading pathogens might improve the&#xD;
      therapeutic efficiency of heparin in sepsis, and this merits future investigations.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In clinical patients, the major pathogens of sepsis caused by abdominal infection are mostly&#xD;
      Gram-negative bacterium. Therefore, aim of this study is to determine effects of low dose&#xD;
      unfractionated heparin for treatment of sepsis caused by abdominal infection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 20, 2021</start_date>
  <completion_date type="Anticipated">July 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-Cause Mortality</measure>
    <time_frame>28 Days after randomization</time_frame>
    <description>Death from all causes at 28-days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death in ICU</measure>
    <time_frame>28 Days after randomization</time_frame>
    <description>Death from all causes at ICU discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SOFA score</measure>
    <time_frame>Day 0,3,6 after randomization</time_frame>
    <description>Total Sequential Organ Failure Assessment (SOFA) score(0-24) , higher values represent a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>APACHEⅡ</measure>
    <time_frame>Day 0,3,6 after randomization</time_frame>
    <description>Acute Physiology and Chronic Health Evaluation (include Acute physiology score, APS and age and Chronic physiology score, totally 0-71 Points)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SIC score</measure>
    <time_frame>Day 0,3,6 after randomization</time_frame>
    <description>Sepsis-induced coagulopathy score (totally 0-6 Points)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DIC score</measure>
    <time_frame>Day 0,3,6 after randomization</time_frame>
    <description>Disseminated intravascular coagulation score (totally 0-8 Points)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilation and continuous renal replacement therapy</measure>
    <time_frame>28 days after randomization</time_frame>
    <description>Duration of mechanical ventilation and continuous renal replacement therapy in ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU stay</measure>
    <time_frame>28 days after randomization</time_frame>
    <description>Duration of stay in ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation</measure>
    <time_frame>0,3,6 days after randomization</time_frame>
    <description>Concentration of inflammation markers such as c-reactive protein, procalcitonin, IL-1β and IL-1α at 0, 3,6 days after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulation</measure>
    <time_frame>0,3,6 days after randomization</time_frame>
    <description>Concentration of coagulation related indexes such as fibrinogen degradation products, d-dimer, thrombin-antithrombin complex, plasminogen activator inhibitor-1, plasmin antiplasmin complex, and thrombomodulin at 0,3,6 days after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of major bleeding</measure>
    <time_frame>28 days after randomization</time_frame>
    <description>&quot;Major bleeding&quot; is defined as intracranial bleeding, life-threatening bleeding, or need red blood cell suspension more than 3 units every 24 hours, and last for 2 days</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Sepsis</condition>
  <condition>Gram-Negative Bacterial Infections</condition>
  <condition>Heparin</condition>
  <arm_group>
    <arm_group_label>Unfractionated Heparin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A bottle solution of Heparin Sodium (2ml:12500IU) is added to 48 ml saline and administered intravenously continuously for 24 hours (10 unit/kgBW/hour), which last 5 days or until the death or discharge.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The same amount of 0.9% saline as the heparin group (50ml) will be administered in the placebo group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Unfractionated Heparin</intervention_name>
    <description>10 unit/kgBW/hour continuous infusion for 5 days</description>
    <arm_group_label>Normal saline</arm_group_label>
    <arm_group_label>Unfractionated Heparin</arm_group_label>
    <other_name>Heparin sodium</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients will be eligible for inclusion if all of the inclusion criteria are met:&#xD;
&#xD;
        1.Sepsis-3 criteria from Society of Critical Care Medicine (SCCM) /European Society of&#xD;
        Intensive Care Medicine (ESICM), and the infection site is from abdomen 2.18≤ age ≤75years&#xD;
        3.obtain informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The primary site of infection is from other parts (such as lungs, intracranial, etc.)&#xD;
             except abdomen&#xD;
&#xD;
          2. Diagnosis of sepsis for more than 48 hour&#xD;
&#xD;
          3. Pregnant and lactating women&#xD;
&#xD;
          4. Severe primary disease including unrespectable tumours, blood diseases and Human&#xD;
             Immunodeficiency Virus (HIV);&#xD;
&#xD;
          5. Have a known or suspected adverse reaction to UFH including HIT&#xD;
&#xD;
          6. Have bleeding or high risk for bleeding&#xD;
&#xD;
          7. Have an indication for therapeutic anticoagulation or have taken anticoagulants within&#xD;
             7 days&#xD;
&#xD;
          8. Use of an immunosuppressant or having an organ transplant within the previous 6 months&#xD;
&#xD;
          9. Participating in other clinical trials in the previous 30 days&#xD;
&#xD;
         10. Have received cardiopulmonary resuscitation within 7 days&#xD;
&#xD;
         11. Have terminal illness with a life expectancy of less than 28 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hong Yuan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The third Xiangya Hospital, Central South University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhijun Huang, MD</last_name>
    <phone>0086-13908472564</phone>
    <email>xy3gcp@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The third Xiangya Hospital, Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Min Gao, MD</last_name>
      <phone>0086-13808495303</phone>
      <email>gaomin1@csu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Ben Lu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Tang Y, Wang X, Li Z, He Z, Yang X, Cheng X, Peng Y, Xue Q, Bai Y, Zhang R, Zhao K, Liang F, Xiao X, Andersson U, Wang H, Billiar TR, Lu B. Heparin prevents caspase-11-dependent septic lethality independent of anticoagulant properties. Immunity. 2021 Mar 9;54(3):454-467.e6. doi: 10.1016/j.immuni.2021.01.007. Epub 2021 Feb 8.</citation>
    <PMID>33561388</PMID>
  </reference>
  <reference>
    <citation>Deng M, Tang Y, Li W, Wang X, Zhang R, Zhang X, Zhao X, Liu J, Tang C, Liu Z, Huang Y, Peng H, Xiao L, Tang D, Scott MJ, Wang Q, Liu J, Xiao X, Watkins S, Li J, Yang H, Wang H, Chen F, Tracey KJ, Billiar TR, Lu B. The Endotoxin Delivery Protein HMGB1 Mediates Caspase-11-Dependent Lethality in Sepsis. Immunity. 2018 Oct 16;49(4):740-753.e7. doi: 10.1016/j.immuni.2018.08.016. Epub 2018 Oct 9.</citation>
    <PMID>30314759</PMID>
  </reference>
  <reference>
    <citation>Yang X, Cheng X, Tang Y, Qiu X, Wang Y, Kang H, Wu J, Wang Z, Liu Y, Chen F, Xiao X, Mackman N, Billiar TR, Han J, Lu B. Bacterial Endotoxin Activates the Coagulation Cascade through Gasdermin D-Dependent Phosphatidylserine Exposure. Immunity. 2019 Dec 17;51(6):983-996.e6. doi: 10.1016/j.immuni.2019.11.005. Epub 2019 Dec 10.</citation>
    <PMID>31836429</PMID>
  </reference>
  <reference>
    <citation>Yang X, Cheng X, Tang Y, Qiu X, Wang Z, Fu G, Wu J, Kang H, Wang J, Wang H, Chen F, Xiao X, Billiar TR, Lu B. The role of type 1 interferons in coagulation induced by gram-negative bacteria. Blood. 2020 Apr 2;135(14):1087-1100. doi: 10.1182/blood.2019002282.</citation>
    <PMID>32016282</PMID>
  </reference>
  <reference>
    <citation>Lu Y, Meng R, Wang X, Xu Y, Tang Y, Wu J, Xue Q, Yu S, Duan M, Shan D, Wang Q, Wang H, Billiar TR, Xiao X, Chen F, Lu B. Caspase-11 signaling enhances graft-versus-host disease. Nat Commun. 2019 Sep 6;10(1):4044. doi: 10.1038/s41467-019-11895-2. Erratum in: Nat Commun. 2020 Mar 9;11(1):1349.</citation>
    <PMID>31492850</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 22, 2021</study_first_submitted>
  <study_first_submitted_qc>April 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2021</study_first_posted>
  <last_update_submitted>April 25, 2021</last_update_submitted>
  <last_update_submitted_qc>April 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Third Xiangya Hospital of Central South University</investigator_affiliation>
    <investigator_full_name>Ben Lu</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Intraabdominal Infections</mesh_term>
    <mesh_term>Gram-Negative Bacterial Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Calcium heparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

